| Hillcrest Healthcare Center | |
| 111 E Pemberton Street, Ashland City, Tennessee 37015 | |
| (615) 792-9154 | |
| Name | Hillcrest Healthcare Center |
|---|---|
| Location | 111 E Pemberton Street, Ashland City, Tennessee |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 95 |
| Occupancy Rate | 55.37% |
| Medicare ID (CCN) | 445316 |
| Legal Business Name | Hillcrest Healthcare, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1104838606 |
| Organization Name | HILLCREST HEALTHCARE, LLC |
| Doing Business As | HILLCREST HEALTHCARE, LLC |
| Address | 111 Pemberton Dr, Ashland City, TN 37015 |
| Phone Number | 615-792-9154 |
News Archive
Currently, approximately 1.6 million Virginians live in primary care shortage areas and 2.2 million in mental health care shortage areas (Kaiser Family Foundation, 2019), yet only three percent of Virginia's high school career and technical education courses are in the health sciences.
To ensure that they receive proper care after surgery, patients are frequently referred by hospitals to inpatient facilities such as skilled nursing homes or inpatient rehabilitation centers or to receive home health care and other outpatient services. This type of care, called post-acute care, now accounts for some $62 billion in annual Medicare spending.
Young adults with hostile attitudes or those who don't cope well with stress may be at increased risk for experiencing memory and thinking problems decades later, according to a study published in the March 2, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Currently, approximately 1.6 million Virginians live in primary care shortage areas and 2.2 million in mental health care shortage areas (Kaiser Family Foundation, 2019), yet only three percent of Virginia's high school career and technical education courses are in the health sciences.
To ensure that they receive proper care after surgery, patients are frequently referred by hospitals to inpatient facilities such as skilled nursing homes or inpatient rehabilitation centers or to receive home health care and other outpatient services. This type of care, called post-acute care, now accounts for some $62 billion in annual Medicare spending.
Young adults with hostile attitudes or those who don't cope well with stress may be at increased risk for experiencing memory and thinking problems decades later, according to a study published in the March 2, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 18.92 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 15 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 52.05 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.66 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.92 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 9.47 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.74 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 21.82 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 85.78 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 4.07 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 29.95 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 33.33 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.74 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.69 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 86.58 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 72.57 | 82.93 |
News Archive
Currently, approximately 1.6 million Virginians live in primary care shortage areas and 2.2 million in mental health care shortage areas (Kaiser Family Foundation, 2019), yet only three percent of Virginia's high school career and technical education courses are in the health sciences.
To ensure that they receive proper care after surgery, patients are frequently referred by hospitals to inpatient facilities such as skilled nursing homes or inpatient rehabilitation centers or to receive home health care and other outpatient services. This type of care, called post-acute care, now accounts for some $62 billion in annual Medicare spending.
Young adults with hostile attitudes or those who don't cope well with stress may be at increased risk for experiencing memory and thinking problems decades later, according to a study published in the March 2, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.
Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.
› Verified 3 days ago
Hillcrest Healthcare Center Location: 111 E Pemberton Street, Ashland City, Tennessee 37015 Phone: (615) 792-9154 | |
The Waters Of Cheatham, Llc Location: 2501 River Road, Ashland City, Tennessee 37015 Phone: (615) 792-4948 |